Prevalence and determinants of non-Alcoholic fatty liver disease in lifelines: A large Dutch population cohort

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Van Den Berg, Eline H ^a   Amini, Marzyeh ^a   Schreuder, Tim C M A ^a   Dullaart, Robin P F ^a   Faber, Klaas Nico ^a   Alizadeh, Behrooz Z ^a   Blokzijl, Hans ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL ABUSE; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MARKER; DUTCHMAN; FATTY LIVER INDEX; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; POPULATION RESEARCH; POPULATION SIZE; PREVALENCE; PROSPECTIVE STUDY; SMOKING; THROMBOCYTE COUNT; BLOOD; COMPLICATION; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

ADULT; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTORS;

EID: 85011406124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171502     Document Type: Article

References (45)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. Nature Publishing Group; 2013; 10: 686-690.
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes. Hepatology. 2015.
3. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148: 547-555. doi:10.1053/j.gastro.2014.11.039 PMID: 25461851.
4. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-Term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009; 7: 234-238. doi:10.1016/j.cgh.2008.11.005 PMID: 19049831.
5. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015; 35: 221-235. doi:10.1055/s-0035-1562943 PMID: 26378640.
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37: 917-923. doi:10.1053/jhep.2003.50161 PMID: 12668987.
7. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid Artery Intimamedia Thickness in Nonalcoholic Fatty Liver Disease. The American Journal of Medicine. 2008; 121: 72-78. doi:10.1016/j.amjmed.2007.08.041 PMID: 18187076.
8. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009; 49: 1537-1544. doi:10.1002/hep.22845 PMID: 19291789.
9. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology. 2005; 42: 44-52. doi:10.1002/hep.20734 PMID: 15895401.
10. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132: 112-117. PMID: 10644271.
11. Zois C-D, Baltayiannis G-H, Bekiari A, Goussia A, Karayiannis P, Doukas M, et al. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol. 2010; 16: 3944-3949. doi:10.3748/wjg.v16.i31.3944 PMID: 20712056.
12. Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, et al. Presence and severity of non-Alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012; 56: 234- 240. doi:10.1016/j.jhep.2011.03.020 PMID: 21703178.
13. Caballerõaa L, Pera G, Auladell MA, Toraan P, Muñoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol. 2010; 22: 24-32. doi:10.1097/MEG.0b013e32832fcdf0 PMID: 19730384.
14. Kanerva N, Sandboge S, Kaartinen NE, Maennistoe S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr. 2014; 100: 1133-1138. doi:10.3945/ajcn.114.086074 PMID: 25099548.
15. Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, et al. Non-Alcoholic fatty liver disease in an area of southern Italy: Main clinical, histological, and pathophysiological aspects. J Hepatol. 2001; 35: 568-574. PMID: 11690701.
16. Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-Alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. 2008; 17: 255-260. PMID: 18836616.
17. Suomela E, Oikonen M, Virtanen J, Parkkola R, Jokinen E, Laitinen T, et al. Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. Ann Med. 2015; 47: 40-46. doi:10.3109/07853890.2014.966752 PMID: 25333756.
18. Tarnoki AD, Tarnoki DL, Bata P, Littvay L, Osztovits J, Jermendy G, et al. Heritability of non-Alcoholic fatty liver disease and association with abnormal vascular parameters: A twin study. Liver Int. 2012; 32: 1287-1293. doi:10.1111/j.1478-3231.2012.02823.x PMID: 22651705.
19. van der Voort EAM, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HLA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014; 70: 517-524. doi:10.1016/j.jaad.2013.10.044 PMID: 24373781.
20. Voelzke H, Robinson D-M, Kleine V, Deutscher R, Hoffmann W, Ludemann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005; 11: 1848- 1853. doi:10.3748/wjg.v11.i12.1848 PMID: 15793879.
21. Ludwig U, Holzner D, Denzer C, Greinert A, Haenle MM, Oeztuerk S, et al. Subclinical and clinical hypothyroidism and non-Alcoholic fatty liver disease: A cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord. 2015; 15: 41. doi:10.1186/s12902-015-0030-5 PMID: 26276551.
22. Kotronen A, Yki-Jaervinen H, Maennistoe S, Saarikoski L, Korpi-Hyoevae lti E, Oksa H, et al. Non-Alcoholic and alcoholic fatty liver diseased two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: The FIN-D2D survey. BMC Public Health. 2010; 10: 237. doi:10.1186/1471-2458-10-237 PMID: 20459722.
23. Papatheodoridis GV, Goulis J, Christodoulou D, Manolakopoulos S, Raptopoulou M, Andrioti E, et al. High prevalence of elevated liver enzymes in blood donors: Associations with male gender and central adiposity. Eur J Gastroenterol Hepatol. 2007; 19: 281-287. doi:10.1097/MEG.0b013e328011438b PMID: 17353691.
24. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al. Prevalence and etiology of altered liver tests: A population-based survey in a Mediterranean town. Hepatology. 2005; 41: 1151-1159. doi:10.1002/hep.20689 PMID: 15841464.
25. Stolk RP, Rosmalen JGM, Postma DS, de Boer RA, Navis G, Slaets JPJ, et al. Universal risk factors for multifactorial diseases: Life Lines: A three-generation population-based study. Eur J Epidemiol. 2008; 23: 67-74. doi:10.1007/s10654-007-9204-4 PMID: 18075776.
26. Scholtens S, Smidt N, Swertz MA, Bakker SJL, Dotinga A, Vonk JM, et al. Cohort Profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol. 2015; 44: 1172-1180. doi:10.1093/ije/dyu229 PMID: 25502107.
27. Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N. Representativeness of the Life- Lines Cohort Study. Plos One. 2015; 10: E0137203. doi:10.1371/journal.pone.0137203 PMID: 26333164.
28. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33. doi:10.1186/1471-230X-6-33 PMID: 17081293.
29. European Association for the Study of the Liver (EASL). Electronic address: Easloffice@easloffice.eu, European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-Alcoholic fatty liver disease. J Hepatol. 2016.
30. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752. doi:10.1161/CIRCULATIONAHA.105.169404 PMID: 16157765.
31. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145: 247-254. PMID: 16908915.
32. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 766-772. doi:10.1373/clinchem.2006.077180 PMID: 17332152.
33. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-1395. doi:10.1002/hep.20466 PMID: 15565570.
34. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-Alcoholic steatohepatitis (NASH) and advanced fibrosis in non-Alcoholic fatty liver disease (NAFLD). Liver Int. 2013; 33: 1398-1405. doi:10.1111/liv.12226 PMID: 23763360.
35. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008; 87: 801-809. PMID: 18400700.
36. Yuan H, Shyy JY-J, Martins-Green M. Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. J Hepatol. 2009; 51: 535-547. doi:10.1016/j.jhep.2009.03.026 PMID: 19556020.
37. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagea-Yared M-H, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut. 2009; 58: 825-832. doi:10.1136/gut.2007.140087 PMID: 18403495.
38. Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol. 2012; 56: 241-247. doi:10.1016/j.jhep.2011.05.027 PMID: 21756851.
39. Yilmaz Y, Senates E, Ayyildiz T, Colak Y, Tuncer I, Ovunc AOK, et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest. 2012; 42: 411-418. doi:10.1111/j.1365-2362.2011.02597.x PMID: 21913918.
40. Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari G, Iraj B. Relationship between nonalcoholic fatty liver disease and inflammation in patients with non-Alcoholic fatty liver. Adv Biomed Res. 2016; 5: 28. doi:10.4103/2277-9175.176368 PMID: 27014655.
41. Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology. 2003; 144: 2195-2200. doi:10.1210/en.2003-0285 PMID: 12746274.
42. Dullaart RPF, Gruppen EG, Connelly MA, Lefrandt JD. A pro-inflammatory glycoprotein biomarker is associated with lower bilirubin in metabolic syndrome. Clin Biochem. 2015; 48: 1045-1047. doi:10.1016/j.clinbiochem.2015.06.016 PMID: 26129880.
43. Day CP. Non-Alcoholic fatty liver disease: current concepts and management strategies. Clin Med (Lond). 2006; 6: 19-25.
44. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. Hepatology (Baltimore, Md.). 2009. pp. 1017-1044.
45. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014; 40: 1209-1222. doi:10.1111/apt.12963 PMID: 25267215.